Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In view of the global emergency posed by lack of access to highly active antiretroviral therapy (HAART) and the limitations of current drug regimens, alternative therapeutic strategies are urgently needed. Cellular immune responses elicited by HIV-1 exert some control over virus replication, therefore the enhancement of HIV-1-specific responses by therapeutic vaccination might lead to viral containment without HAART. We evaluated the safety and immunogenicity, in HIV-1-infected individuals under HAART suppression, of a DNA vaccine, pTHr.HIVA.

Type

Journal article

Journal

AIDS

Publication Date

12/08/2005

Volume

19

Pages

1321 - 1323

Keywords

AIDS Vaccines, Adult, Antiretroviral Therapy, Highly Active, Cohort Studies, Drug Evaluation, Enzyme-Linked Immunosorbent Assay, Epitopes, Female, Genes, gag, HIV Infections, HIV-1, Humans, Immunity, Cellular, Immunization, Leukocytes, Mononuclear, Male, Vaccines, DNA